

## Product Data Sheet

Product Name: HK2-IN-4

Cat. No.: GC79709

### Chemical Properties

Cas. No. 2748366-80-3


Formula  $C_{24}H_{25}NO_4$  M.Wt 391.46

Solubility DMSO: 100 mg/mL (255.45 mM; Need ultrasonic) Storage Store at 4°C, protect from light

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



### Background

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

## Product Data Sheet

---

HK2-IN-4 is a selective hexokinase 2 ( HK2 ) inhibitor with an IC<sub>50</sub> value of 0.79 μM and a K<sub>d</sub> value of 0.41 μM. HK2-IN-4 blocks the interaction between HK2 and voltage-dependent anion channel 1 ( VDAC1 ). HK2-IN-4 reduces lactate and ATP levels in cancer cells. HK2-IN-4 induces the production of apoptosis ( apoptosis ) markers in cancer cells, including increased p-AMPK/AMPK ratio and Bax levels, as well as decreased Bcl2 levels. HK2-IN-4 inhibits the proliferation of cancer cells with high HK2 expression. HK2-IN-4 can be used in research related to colorectal cancer and non-small cell lung cancer [1].

In Vitro, HK2-IN-4 (Compound 106) (5 μM; 30 min) potently and selectively inhibits the activity of recombinant HK2 enzyme, with an IC<sub>50</sub> of 0.79 μM, while its IC<sub>50</sub> values against HK1, HK3 and HK4 are 78.47 μM, 60.86 μM and 46.14 μM, respectively<sup>[1]</sup>. HK2-IN-4 (10-100 μM; 24-72 h) selectively inhibits the viability of colorectal cancer cells with high HK2 expression (SW480, LOVO, HCT116), with an IC<sub>50</sub> value as low as 5.00 μM after 72 h under hypoxic conditions; compared with normoxic conditions, its efficacy is enhanced under hypoxic conditions, and its cytotoxicity depends on HK2 expression<sup>[1]</sup>. HK2-IN-4 (0-40 μM; 6 h) reduces mitochondrial HK2 levels in HCT116 and SW480 cells in a dose-dependent manner under hypoxic conditions<sup>[1]</sup>. Treatment with HK2-IN-4 (50 μM; 7 h) significantly reduces the colocalization level of HK2 and VDAC1 in SW480 cells and disrupts the HK2-VDAC1 interaction<sup>[1]</sup>. HK2-IN-4 (50-100 μM; 2 h) inhibits glycolysis in SW480 and HCT116 WT cells under hypoxic conditions, but exerts no such effect on HK2 KO cells, indicating that its glycolysis-inhibiting effect is HK2-dependent<sup>[1]</sup>. HK2-IN-4 (2.5-20 μM; 12-24 h) reduces lactate and ATP levels in hypoxic SW480 colorectal cancer cells in a dose-dependent manner, increases the p-AMPK/AMPK ratio, regulates the expression levels of Bax/Bcl2, and induces bioenergetic stress and apoptosis<sup>[1]</sup>.

### References:

[1]. Shan W, et al. AI-driven identification of a selective dual function inhibitor blocking HK2 activity and HK2-VDAC1 interaction displaying enhanced anticancer efficacy under hypoxia. Eur J Med Chem. 2026;309:118752.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA